Pharmacogenomics of interferon-beta therapy in multiple sclerosis: baseline IFN signature determines pharmacological differences between patients.

Pharmacogenomics of interferon-beta therapy in multiple sclerosis: baseline IFN signature determines pharmacological differences between patients.

<h4>Background</h4>Multiple sclerosis (MS) is a heterogeneous disease. In order to understand the partial responsiveness to IFNbeta in Relapsing Remitting MS (RRMS) we studied the pharmacological effects of IFNbeta therapy.<h4>Methodology</h4>Large scale gene expression profi...

Full description

Bibliographic Details
Main Authors: Lisa G M van Baarsen, Saskia Vosslamber, Marianne Tijssen, Josefien M C Baggen, Laura F van der Voort, Joep Killestein, Tineke C T M van der Pouw Kraan, Chris H Polman, Cornelis L Verweij
Format: Article
Language:English
Published: Public Library of Science (PLoS) 2008-04-01
Series:PLoS ONE
Online Access:https://www.ncbi.nlm.nih.gov/pmc/articles/pmid/18382694/pdf/?tool=EBI

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/pmid/18382694/pdf/?tool=EBI

Similar Items